The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk

Tumor Biology

Volumn 35, Issue 8, 2014, Pages 8319-8328

  Fu, Chenying ^a   Dong, Wen Qi ^a   Wang, Ani ^b   Qiu, Guozhen ^c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

ESR; Meta analysis; Polymorphism; Prostate cancer; rs1256049; rs9340799

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; ESTROGEN RECEPTOR BETA;

ASIAN CONTINENTAL ANCESTRY GROUP; BLACK PERSON; CAUCASIAN; ETHNOLOGY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; META ANALYSIS; PROSTATIC NEOPLASMS; RISK;

AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK;

EID: 84922391341     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2086-7     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Becker N. Epidemiology of prostate cancer. Radiologe. 2011;51:922–9.
3. McDougall JA, Li CI. Trends in distant-stage breast, colorectal, and prostate cancer incidence rates from 1992 to 2004: potential influences of screening and hormonal factors. Horm Cancer. 2010;1:55–62.
4. Harkonen PL, Makela SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol. 2004;92:297–305.
5. Ellem SJ, Risbridger GP. The dual, opposing roles of estrogen in the prostate. Ann N Y Acad Sci. 2009;1155:174–86.
6. Menasce LP, White GR, Harrison CJ, Boyle JM. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics. 1993;17:263–5.
7. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997;82:4258–65.
8. Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation. 2002;105:1879–82.
9. Maguire P, Margolin S, Skoglund J, Sun XF, Gustafsson JA, Borresen-Dale AL, et al. Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer. Breast Cancer Res Treat. 2005;94:145–52.
10. Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:1869–80.
11. Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, et al. Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab. 2011;96:E368–72.
12. Balistreri CR, Caruso C, Carruba G, Miceli V, Candore G. Genotyping of sex hormone-related pathways in benign and malignant human prostate tissues: data of a preliminary study. OMICS. 2011;15:369–74.
13. Szendroi A, Speer G, Tabak A, Kosa JP, Nyirady P, Majoros A, et al. The role of vitamin D, estrogen, calcium sensing receptor genotypes and serum calcium in the pathogenesis of prostate cancer. Can J Urol. 2011;18:5710–6.
14. Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Estrogen Receptors Alpha (rs2234693 and rs9340799), and Beta (rs4986938 and rs1256049) Genes polymorphism in prostate cancer: evidence for association with risk and histopathological tumor characteristics in Iranian men. Mol Carcinog. 2012;51 Suppl 1:E104–17.
15. Jurecekova J, Sivonova MK, Evinova A, Kliment J, Dobrota D. The association between estrogen receptor alpha polymorphisms and the risk of prostate cancer in Slovak population. Mol Cell Biochem. 2013;381:201–7.
16. Hernandez J, Balic I, Johnson-Pais TL, Higgins BA, Torkko KC, Thompson IM, et al. Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol. 2006;175:523–7.
17. Chen YC, Kraft P, Bretsky P, Ketkar S, Hunter DJ, et al. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2007;16:1973–81.
18. Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA, et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res. 2001;7:3092–6.
19. Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, et al. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer. 2003;98:1411–6.
20. Fukatsu T, Hirokawa Y, Araki T, Hioki T, Murata T, Suzuki H, et al. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res. 2004;24:2431–7.
21. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:969–78.
22. Gupta L, Thakur H, Sobti RC, Seth A, Singh SK. Role of genetic polymorphism of estrogen receptor-alpha gene and risk of prostate cancer in north Indian population. Mol Cell Biochem. 2010;335:255–61.
23. Sonoda T, Suzuki H, Mori M, Tsukamoto T, Yokomizo A, Naito S, et al. Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men. Eur J Cancer Prev. 2010;19:131–7.
24. Nicolaiew N, Cancel-Tassin G, Azzouzi AR, Grand BL, Mangin P, Cormier L, et al. Association between estrogen and androgen receptor genes and prostate cancer risk. Eur J Endocrinol. 2009;160:101–6.
25. Sun YH, Yang B, Wang XH, Xu CL, Gao XF, Gao X, et al. Association between single-nucleotide polymorphisms in estrogen receptor beta gene and risk of prostate cancer. Chin J Surg. 2005;43:948–51.
26. Ding X, Cui FM, Xu ST, Pu JX, Huang YH, Zhang JL. Variants on ESR1 and their association with prostate cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:3931–6.
27. Wang YM, Liu ZW, Guo JB, Wang XF, Zhao XX, Zheng X. ESR1 Gene polymorphisms and prostate cancer risk: a HuGE review and meta-analysis. PLoS One. 2013;21:e66999.
28. Gu Z, Wang G, Chen W. Estrogen receptor alpha gene polymorphisms and risk of prostate cancer: a meta-analysis involving 18 studies. Tumor Biol. 2014. doi:10.1007/s13277-014-1785-4.
29. Hu ZY, Yu Q, Pei Q, Guo C. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res. 2010;16:3832–42.
30. Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;24:1291–306.
31. Wang T, Wang B. Association between glutathione S-transferase M1/glutathione S-transferase T1 polymorphisms and Parkinson's disease: a meta-analysis. J Neurol Sci. 2014;338:65–70.
32. Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21:3672–3.
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
34. Mullen B, Muellerleile P, Bryant B. Cumulative meta-analysis: a consideration of indicators of sufficiency and stability. Pers Soc Psychol Bull. 2001;27:1450–62.
35. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
36. Dual S, Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95:89–98.
37. Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13:840–8.
38. Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol. 2009;55:533–42.
39. Attia DM, Ederveen AG. Opposing roles of ER-alpha and ER-beta in the genesis and progression of adenocarcinoma in the rat ventral prostate. Prostate. 2012;72:1013–22.
40. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol. 2005;34:1319–28.
41. Ushiyama T, Ueyama H, Inoue K, Nishioka J, Ohkubo I, Hukuda S. Estrogen receptor gene polymorphism and generalized osteoarthritis. J Rheumatol. 1998;25:134–7.
42. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet. 2003;12:205–16.